These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16180892)

  • 21. Drug impurities: problems and regulations.
    Pifferi G; Mannucci A
    Boll Chim Farm; 1999 Nov; 138(10):500-7. PubMed ID: 10765465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.
    Crivori P; Morelli A; Pezzetta D; Rocchetti M; Poggesi I
    Eur J Pharm Sci; 2007 Nov; 32(3):169-81. PubMed ID: 17714921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mining a chemical database for fragment co-occurrence: discovery of "chemical clichés".
    Lameijer EW; Kok JN; Bäck T; Ijzerman AP
    J Chem Inf Model; 2006; 46(2):553-62. PubMed ID: 16562983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination and mapping of activity-specific descriptor value ranges for the identification of active compounds.
    Eckert H; Bajorath J
    J Med Chem; 2006 Apr; 49(7):2284-93. PubMed ID: 16570925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Computational aqueous solubility prediction for drug-like compounds in congeneric series.
    Du-Cuny L; Huwyler J; Wiese M; Kansy M
    Eur J Med Chem; 2008 Mar; 43(3):501-12. PubMed ID: 17574307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ring systems in mutagenicity databases.
    Kho R; Hodges JA; Hansen MR; Villar HO
    J Med Chem; 2005 Oct; 48(21):6671-8. PubMed ID: 16220983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-view spectral clustering and its chemical application.
    Adefioye AA; Liu X; De Moor B
    Int J Comput Biol Drug Des; 2013; 6(1-2):32-49. PubMed ID: 23428472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Introduction of an information-theoretic method to predict recovery rates of active compounds for Bayesian in silico screening: theory and screening trials.
    Vogt M; Bajorath J
    J Chem Inf Model; 2007; 47(2):337-41. PubMed ID: 17302401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global mapping of pharmacological space.
    Paolini GV; Shapland RH; van Hoorn WP; Mason JS; Hopkins AL
    Nat Biotechnol; 2006 Jul; 24(7):805-15. PubMed ID: 16841068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. QSPR correlation of melting point for drug compounds based on different sources of molecular descriptors.
    Modarresi H; Dearden JC; Modarress H
    J Chem Inf Model; 2006; 46(2):930-6. PubMed ID: 16563024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A screening study of ChirBase molecular database to explore the expanded chiral pool derived from the application of chiral chromatography.
    Piras P; Roussel C
    J Pharm Biomed Anal; 2008 Apr; 46(5):839-47. PubMed ID: 17942261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification and characterization of a principal oxidation impurity in clopidogrel drug substance and drug product.
    Mohan A; Hariharan M; Vikraman E; Subbaiah G; Venkataraman BR; Saravanan D
    J Pharm Biomed Anal; 2008 May; 47(1):183-9. PubMed ID: 18313249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of 2D fingerprint methods for multiple-template similarity searching on compound activity classes of increasing structural diversity.
    Tovar A; Eckert H; Bajorath J
    ChemMedChem; 2007 Feb; 2(2):208-17. PubMed ID: 17143917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ChemGPS-NP: tuned for navigation in biologically relevant chemical space.
    Larsson J; Gottfries J; Muresan S; Backlund A
    J Nat Prod; 2007 May; 70(5):789-94. PubMed ID: 17439280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development.
    Dobo KL; Greene N; Cyr MO; Caron S; Ku WW
    Regul Toxicol Pharmacol; 2006 Apr; 44(3):282-93. PubMed ID: 16464524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Scaffold distributions in bioactive molecules, clinical trials compounds, and drugs.
    Hu Y; Bajorath J
    ChemMedChem; 2010 Feb; 5(2):187-90. PubMed ID: 20014088
    [No Abstract]   [Full Text] [Related]  

  • 37. Relationship between HPLC precision and number of significant figures when reporting impurities and when setting specifications.
    Agut C; Segalini A; Bauer M; Boccardi G
    J Pharm Biomed Anal; 2006 May; 41(2):442-8. PubMed ID: 16472956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemical database mining through entropy-based molecular similarity assessment of randomly generated structural fragment populations.
    Batista J; Bajorath J
    J Chem Inf Model; 2007; 47(1):59-68. PubMed ID: 17238249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural identification and characterization of impurities in ceftizoxime sodium.
    Bharathi Ch; Prasad ChS; Bharathi DV; Shankar R; Rao VJ; Dandala R; Naidu A
    J Pharm Biomed Anal; 2007 Jan; 43(2):733-40. PubMed ID: 16950586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance.
    Bercu JP; Hoffman WP; Lee C; Ness DK
    Regul Toxicol Pharmacol; 2008 Aug; 51(3):270-7. PubMed ID: 18550240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.